NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies.

10 equities research analysts have issued twelve-month price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $16.00 to $73.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $37.75 in the next year. This suggests a possible upside of 52.8% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

Press coverage about ITCI stock has been trending very negative this week, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 6,540,000 shares, a decline of 21.9% from the January 15th total of 8,370,000 shares. Based on an average daily volume of 2,790,000 shares, the short-interest ratio is presently 2.3 days. Currently, 14.0% of the company's shares are short sold. View Intra-Cellular Therapies' Current Options Chain.

Some companies that are related to Intra-Cellular Therapies include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), Nektar Therapeutics (NKTR), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Mirati Therapeutics (MRTX), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Zai Lab (ZLAB), SAGE Therapeutics (SAGE) and PTC Therapeutics (PTCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT), Crispr Therapeutics (CRSP), Gilead Sciences (GILD) and Clovis Oncology (CLVS).

Intra-Cellular Therapies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (11.41%), State Street Corp (2.01%), Candriam Luxembourg S.C.A. (1.61%), Schroder Investment Management Group (1.36%), Geode Capital Management LLC (1.15%) and Rhenman & Partners Asset Management AB (0.90%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Schroder Investment Management Group, Rhenman & Partners Asset Management AB, State Street Corp, Candriam Luxembourg S.C.A., Geode Capital Management LLC, General American Investors Co. Inc. and Franklin Street Advisors Inc. NC. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

ITCI stock was purchased by a variety of institutional investors in the last quarter, including DCF Advisers LLC, FMR LLC, First Midwest Bank Trust Division, LMR Partners LLP, Goldman Sachs Group Inc., UBS Group AG, Raymond James & Associates and Palo Alto Investors LP. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $24.70.

Intra-Cellular Therapies has a market capitalization of $1.37 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]